This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Tables [5] 2 ABSTRACT Background: Paraoxonase-1 (PON-1) has been suggested to be associated with cardiovascular disease (CVD) risk, however, aspects of the association, such as shape and independence from conventional risk factors are still uncertain. We aimed to assess the association of PON-1 with CVD risk and determine its potential utility for CVD risk prediction.
Introduction
The inverse and independent association of high-density lipoprotein cholesterol (HDL-C) with atherosclerotic cardiovascular disease (CVD) is well known, 1 and is commonly ascribed to the functional properties of this lipoprotein fraction. 2 HDL promotes the reverse cholesterol transport pathway, by stimulating efflux of cholesterol out of macrophages in the arterial wall and exerts antioxidant, antiinflammatory, antithrombotic, and endothelial cell maintenance properties. [3] [4] [5] [6] Paraoxonase-1 (PON-1) is a HDL-bound esterase enzyme with well-established antioxidant functions, which is synthesized by the liver. 7 It hydrolyses lipid peroxides, thereby protecting low-density lipoproteins (LDLs) from oxidative modifications. Recent studies in rodent models and humans have suggested that the anti-atherogenic and cardioprotective effects of the HDL fraction are primarily attributable to PON-1 activity. 8 Serum PON-1 activity has been shown to be reduced in patients with stable coronary artery disease, post-myocardial infarction patients, and in patients at increased CVD risk such as hypercholesterolaemia, metabolic syndrome, and type 2 diabetes.
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Emerging evidence indicates that PON-1 activity may be linked to CVD risk. Two published literature-based meta-analyses have assessed the relationship between PON-1 activity and coronary heart disease (CHD) risk. 12, 13 However, because they only compared PON-1 activity in CHD cases and non-CHD controls, the nature, shape, and magnitude of the prospective association could not be addressed. A number of population-based prospective studies have generally reported inverse associations between PON-1 activity and CVD outcomes. [14] [15] [16] [17] [18] [19] Some of these reports were relatively small or did not adjust for potential confounders. Data on the prospective associations in approximately healthy ("general") populations are also sparse. Among the limited studies that have been based in general populations, some reported inverse associations, 15, 17 with majority reporting null associations. 14, 15, 20, 21 For these reasons, the nature of the shape, magnitude, and independence of the association between PON-1 activity and CVD risk in general population settings remains uncertain. There are suggestions that PON-1 might be a better atherosclerotic CVD risk factor compared to HDL-C, 22 and there is a growing interest in the potential value of PON-1 in CVD risk prevention. There is therefore a requirement for an adequately powered and comprehensive assessment of the association of baseline PON-1 activity with risk of future first-ever CVD events using long-term observational evidence in the general population. Our primary aim was to characterize the shape and assess the magnitude and independence of the prospective association between PON-1 activity and CVD risk, using a large population-based sample of 6902 participants free from preexisting CVD at baseline. A secondary aim was to investigate the extent to which PON-1 activity could improve the prediction of first-onset CVD outcomes in general population settings when added to a conventional CVD risk prediction model. Finally, to contextualize these findings, we report a metaanalysis of available published prospective evidence on the associations of baseline PON-1 activity and risk of CVD in general population settings.
Materials and methods

Participants
The study population consisted of inhabitants living in the city of Groningen in the Netherlands.
Subjects were participants in the Prevention of Renal and Vascular End-stage Disease (PREVEND) study, an observational, general population-based prospective cohort study designed to investigate the natural course of urinary albumin excretion and its relationship to renal disease and CVD and which began in 1997. The description of the study design and recruitment processes have been described in detail previously. 23 The baseline cohort (n=8592) was recruited from participants who were aged 28-75 years and had baseline measurements performed between 1997 and 1998. For the present analyses, participants with a prevalent history of CVD, liver disease, renal disease, or malignancy were excluded and the final cohort comprised of 6902 subjects with non-missing information on serum PON-1 activity, several CVD risk markers, and cardiovascular outcomes. The medical ethics committee of the University Medical
Center Groningen approved the PREVEND study and which was conducted in accordance with the Declaration of Helsinki. Informed written consent was provided by each participant and was documented in a consent form approved by the medical ethics committee.
Risk factor assessment
Baseline data on demographics, physical measurements (including anthropometrics), and cardiovascular risk factors were assessed during two outpatient visits by study participants. After an overnight fast and 15 minutes of rest, venous blood was obtained from participants. Plasma samples were prepared by centrifugation at 4 ºC. Sera was stored at -20 ºC and heparinized plasma samples stored at -80 ºC from baseline collection until analysis. The analysis of serum PON-1 enzymatic activity was conducted in 2014 and was measured as its arylesterase activity, i.e. as the rate of hydrolysis of phenyl acetate into phenol, which has been described previously. 24 The inter-assay CV was 8%. Arylesterase activity, measured with this assay, is positively correlated PON-1 enzymatic activity toward paraoxon.
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Given the virtual absence of free PON-1 in serum, as determined by gelfiltration, 26 its activity was essentially measured as HDL-bound PON-1 activity, which was consistent with several large-scale epidemiological studies of this nature. Plasma glucose, total cholesterol, apolipoproteins (Apo) A-1 and B, HDL-C, high sensitivity C-reactive protein (hsCRP), triglycerides, total bilirubin, serum creatinine, and serum cystatin C were measured using standard methods described previously. 
Endpoint ascertainment
The primary endpoint in our study was first-onset CVD, with subsidiary analyses of incident CHD and stroke endpoints. The dates and causes of death were obtained by record linkage with the Dutch Central Bureau of Statistics. Information on hospitalization for cardiovascular morbidity was received from PRISMANT, the Dutch national registry of hospital discharge diagnoses. 34 Until 01-01-2009, all data were coded according to the International Classification of Diseases, Ninth Revision (ICD-9). After this date, data were coded according to ICD-10 codes. First-onset CVD was defined as the combined endpoint of acute myocardial infarction, acute and subacute ischemic heart disease, coronary artery bypass grafting or percutaneous transluminal coronary angioplasty, subarachnoid hemorrhage, intracerebral hemorrhage, other intracranial hemorrhage, occlusion or stenosis of the precerebral or cerebral arteries, and other vascular interventions such as percutaneous transluminal angioplasty or bypass grafting of peripheral vessels and aorta. Coronary heart disease events were defined as fatal or nonfatal myocardial infarction, ischemic heart disease, coronary artery bypass grafting, and percutaneous transluminal coronary angioplasty. Stroke events were defined as subarachnoid hemorrhage, intracerebral haemorrhage, other and unspecified intracranial haemorrhage, and occlusion and stenosis of precerebral or cerebral arteries.
Further details on the definition of cardiovascular outcomes are also provided in Appendix Supplement 1.
Statistical analyses
Prospective cohort analyses Variables that were skewed (e.g., PON-1 activity, hsCRP, triglycerides, creatinine, and total bilirubin) were natural logarithm (loge) transformed to achieve approximately normal distributions. Baseline characteristics of participants were summarized using descriptive analyses. Partial correlation coefficients (adjusted for age and sex) were calculated to assess the cross-sectional associations of serum PON-1 activity with CVD risk markers. Analyses of the association between serum PON-1 activity and CVD risk involved Cox proportional hazards models after confirmation of assumptions of proportionality of hazards. 40 For participants with at least 10 years of follow-up, reclassification was assessed using the netreclassification-improvement (NRI). 41 Reclassification analysis was based on predicted 10-year CVD risk categories of low (<5%), intermediate (5 to <7.5%), and high (≥7.5%) risk. 42 In subsidiary analyses, we also performed risk discrimination and reclassification analyses based on the Reynolds Risk Score (RRS). 43, 44 Risk prediction analysis was restricted to participants without a known history of diabetes or CVD at baseline.
Literature review and meta-analysis We conducted a meta-analysis using a predefined protocol and in accordance with the PRISMA (Appendix Supplement 2) and MOOSE guidelines 14,15 (Appendix Supplement 3). We sought prospective cohort studies that have assessed the association between PON-1 activity and CVD risk published up to July 2015 using MEDLINE, EMBASE, and Science Citation Index databases as well as scanning reference lists from the included articles. The computer-based searches combined free and MeSH search terms and combination of key words related to the exposure (e.g., "paraoxonase-1", "arylesterase", etc.) and outcome (e.g., "cardiovascular disease", "coronary heart disease", "stroke", etc.). Further details on the search strategy are presented in Appendix Supplement 4.
Studies were eligible if they had at least one year of follow-up and recruited participants from approximately general populations as previously described. 45 The primary endpoint of this analysis was any CVD event (i.e., composite CVD, CHD, or stroke). A pooled estimate was also assessed for CHD outcomes. Appendix Supplement 1 provides details of study-specific endpoint definitions. Study quality was assessed based on the Newcastle-Ottawa Scale (NOS) method.
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Summary measures were presented as relative risks (RRs) with 95% confidence intervals (CIs). We assumed hazard ratios and odds ratios to approximate the same measure of RRs. To enhance consistency, reported study-specific RRs were transformed to per 1SD change in baseline PON-1 values using standard statistical methods 47, 48 which have been described in detail previously. 45 The summary RR (including the estimate from the present study) was calculated using random effects meta-analysis. All statistical analyses were conducted using Stata version 14 (Stata Corp, College Station, Texas).
Results
Results from the PREVEND cohort
Baseline Characteristics and Correlates of paraoxonase-1 Activity
Data were available for 6902 participants without a known history of CVD at baseline. The mean age of overall participants at baseline was 48 (SD 12) years and 52% were women. ( Table 1 were lower by 6% in people with diabetes compared with people without diabetes and by 14% in people on regular glucose lowering medication compared with non-users ( Table 2) . Table   3 ). In an age-and sex-adjusted analysis, the initial association 0.90 (95% CI, 0.84 to 0.97; P=0.004) was attenuated after single additional adjustment for HDL-C 0.96 (95% CI, 0.89 to 1.03; P=0.249).
Substituting total cholesterol and HDL-C for apolipoproteins B and A-1 respectively resulted in similar associations (data not shown). HRs were similar in analyses that excluded CVD outcomes recorded in the first two years of follow-up, participants on regular antihypertensive medication, and participants on regular lipid-lowering medication ( Table 4) . The associations did not vary significantly by levels or categories of several clinically relevant individual characteristics, except for suggestion of effect modification by BMI (P for interaction = 0.026) and smoking (P for interaction = 0.053) ( Figure 2 ). In separate analyses for CHD and stroke, the approximately log-linear inverse association of PON-1 with CHD in analyses adjusted for several established risk factors and potential confounders was somewhat attenuated on additional adjustment for HDL-C (Table 3; Figure 3 ) and there was no statistically significant evidence of an association with stroke ( Table 3) . To put the strength of the association of PON-1 activity with CVD risk into context, direct comparisons were made to associations of HDL-C with CVD, CHD, and stroke outcomes. Serum HDL-C concentrations were inversely and independently associated with CVD and CHD outcomes. The associations were also independent of serum PON-1 activity. There was no evidence of an association with stroke outcomes (Table 5) . Similar findings were found in analysis with Apo A-I instead of HDL-C (data not shown).
Paraoxonase-1 Activity and CVD Risk Prediction
Addition of HDL-C measurements to a prognostic model for first cardiovascular events that included data on age, sex, smoking status, blood pressure, and total cholesterol increased the C-index by 0.0034 Literature-based meta-analyses
Literature Search, Characteristics, and Quality of Eligible Studies
The initial search identified 1986 potentially relevant citations. After screening and detailed assessment, 5 articles based on 5 unique population-based studies were included ( Figure 4 ). Therefore we metaanalyzed estimates from 6 studies (including the current study) involving a total of 15 064 unique participants with 2958 incident CVD outcomes reporting on the association between PON-1 activity and CVD risk. Detailed characteristics of these studies and quality assessment have been summarized in Appendix Supplements 7-8
Paraoxonase-1 Activity and CVD Risk in Pooled Analysis
Of the six studies, three studies (including the current study) provided risk estimates for PON-1 as measured by its arylesterase activity (using phenyl acetate as substrate) 17, 20 and the other three reported estimates for PON-1 as measured by paraoxonase activity (using paraoxon as substrate). 15, 16, 21 Both assay systems were used in two studies 17, 20 (Appendix Supplement 7). Including the current study, the overall pooled unadjusted or age-adjusted RR (95% CI) medication. Similar associations were observed for CHD risk. However, there was no statistically significant evidence of an association with stroke, consistent with the findings for HDL-C in the same set of participants. Uncertainties still exist for the association between HDL-C and stroke, particularly for stroke subtypes; 49 however, there is a possibility that the current findings may be attributed to the low event rate for stroke in our study. There is also a possibility that the null findings for stroke could be due to the combined endpoints of different stroke subtypes, with different aetiologies. We were however unable to conduct separate analyses for the subtypes of stroke because of the very low event rates in each endpoint. Given that no previous study has evaluated the association of PON-1 activity and strokespecific outcomes, larger-scale studies are warranted to confirm or refute these findings. Results from assessments of improvements in measures of risk discrimination and reclassification, indicate that additional information on PON-1 measurements provides no significant improvement in CVD risk prediction.
Pooled findings from the systematic meta-analysis of the six available studies showed that PON-1 was inversely associated with CVD risk in unadjusted or age-adjusted analysis. In the PREVEND study, we measured PON-1 activity as its arylesterase activity (with phenyl acetate as substrate) which was driven by previous documentation that arylesterase activity is less variable between subjects compared to its activity towards paraoxon, and is closely correlated with PON-1 mass. 7, 25 In view of this, we also grouped the studies included in the meta-analysis according to the type of PON-1 activity assay. Indeed, in unadjusted or age-adjusted analysis, the risk estimate for PON-1 as arylesterase activity was stronger than that of PON-1 as paraoxonase activity. Further adjustment for established risk factors (including HDL-C) showed a less robust association of PON-1 activity with incident CVD, confirming the suggestion that the inverse association between PON-1 activity and CVD risk is partly dependent on HDL-C concentrations.
Possible explanations for findings
Our results indicate that PON-1 is inversely associated with CVD (including CHD) risk, independent of several established risk factors except for HDL-C. Though the majority of previous studies conducted in the general population have failed to demonstrate an inverse independent association, 14-16, 21 the dependency of the association on HDL-C has previously been reported. 15, 16 The attenuation of the association on adjustment for HDL-C is expected, given that PON-1 is an important component of HDL, 50-53 which acts as its carrier and site of action. Plausible biologic mechanisms by which PON-1 contributes to reduced CVD risk is through the inhibition of LDL oxidation, 54 which is believed to play a central role in the development of atherosclerosis. 55 PON-1 is also involved in the destruction of proinflammatory oxidised phospholipids (involved in the development and progression of atherosclerotic lesions 56 ) which are present in oxidised LDLs, 57 decreases the lipid peroxide content in arterial lesions, could promote cholesterol efflux, and also prevents HDL from being oxidized. 
Strengths and limitations
The strengths of the current study deserve consideration. Our study included analyses of primary data as well as a meta-analysis of all available published prospective cohorts in a single comprehensive investigation. It provides the most comprehensive investigation, to date, of the observational epidemiological association between PON-1 activity and CVD risk. PREVEND participants were selected from a sample that was nationally representative, were well characterized, involved a high response and follow-up rates and had been prospectively monitored using established hospital admissions databases and disease endpoints. The PREVEND database had measurements on a comprehensive panel of lifestyle and biological markers that permitted adequate adjustment for potential confounders, hence enabling reliable assessments of the magnitude of associations. The current study had higher statistical power to examine the associations in greater detail, including comparison of the associations at different levels or categories of vascular risk factors and sensitivity analyses to supplement and contextualize the principal findings. Individuals with prevalent CVD at baseline were excluded from the analyses, therefore limiting any possibilities of reverse-causation bias. The PREVEND study participants were suitable for risk prediction analyses because they were followed for a long duration and had complete set of measurements used in standard risk prediction scores. We also carried out several sensitivity analyses to avoid potential bias due to undiagnosed disease at baseline. Despite these, residual biases (i.e., reverse causation) may still remain because of the possibility of subclinical or undetected prevalent disease. On the other hand, the present analysis also has some limitations. In the PREVEND cohort, given the nature of the observational data available, there is a possibility of potential residual confounding due to errors in measurements of risk marker and other unmeasured confounders. Measurements of PON-1 in the PREVEND study involved prolonged serum storage, which could have resulted in under-estimation of the associations due to sample degradation. However, PON-1 is known to show no loss of activity by prolonged storage in frozen samples (-70°C) and on repeated freeze-thawing over two years, with an approximate loss in activity by 20% over seven years. 63 In our analyses, we were unable to show the extent to which baseline PON-1 measurements may underestimate the association between long-term PON-1 activity and CVD outcomes, because of the absence of repeat measurements on PON-1. The analyses were based on a predominantly white-European population, therefore the findings may not be generalisable to individuals of different ethnicities, given that interpopulation differences in serum paraoxonase specific activity (which are independent of differences in serum lipids and lipoprotein concentrations) have been demonstrated in healthy populations. 64 There was substantial heterogeneity between the contributing studies for the meta-analysis and the limited number of studies precluded detailed exploration of heterogeneity; however, our results remained robust in several sensitivity analyses.
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A, Unadjusted; B, adjusted for age and sex; C, adjustment as in B plus smoking status, history of diabetes, systolic blood pressure, and total cholesterol; D, adjustment as in C plus body mass index, alcohol consumption, glucose, loge triglycerides, estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), loge urine albumin excretion, and loge total bilirubin; E, adjustment as in D plus high-density lipoprotein cholesterol; the size of the box is proportional to the inverse of the variance of hazard ratio 
Sex
Males Females
History of diabetes No Yes
Smoking status Non-smokers Current smokers
Alcohol consumption
Non-alcohol consumers Alcohol consumers
Systolic blood pressure (mmHg) < 126 ≥ 126
Total cholesterol (mmol/l) < 5.51 ≥ 5.51
Triglycerides (mmol/l) < 1.14 ≥ 1.14 Estimated GFR (ml/min/1.73 m 2 ) < 98.7 ≥ 98.7
Total bilirubin (µmol/l) < 8 ≥ 8 
HR (95% CI)
.681
.594
.204
.053
.
418
.026
.241
790
.395
.830
.669
.871
P-value* 1 .5
.75 1 1.5
HR (95% CI) per 1SD higher log e PON-1 activity
Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, and total cholesterol; CI, confidence interval (bars); CVD, cardiovascular disease; Estimated GFR, glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; SD, standard deviation; *, P-value for interaction; cut-offs used for body mass index, systolic blood pressure, total cholesterol, HDL-C, triglycerides, estimated GFR, and total bilirubin are median values. Study acronyms are provided in Appendix Supplement 1. The summary estimates were calculated using random effects models; A, results were unadjusted or adjusted for age only; B, results were adjusted for established cardiovascular risk factors including high-density lipoprotein cholesterol; Size of data markers are proportional to the inverse of the variance of the relative risk; CI, confidence interval (bars); CVD, cardiovascular disease; RR, relative risk; SD, standard deviation 
